BlossomHill Therapeutics, Inc.

We're #hiring a new Senior Director, Medical Writing in San Diego, California. Apply today or share this post with your network.

BLOSSOMHILL THERAPEUTICS is looking for an Accounts Payable Specialist!

We're on the road to present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston and also attending the #JeffriesHealthcare Global Conference in London, where we’ll be taking 1x1 meetings to discuss our science and pipeline. See you there!

We're looking forward to the 67th #ASH25 in December, where our team will present a trial-in-progress poster that highlights our ongoing, first-in-human, Phase 1/1b dose escalation study of BH-30236 in relapsed/refractory acute myeloid #leukemia and higher-risk #myelodysplastic syndrome #AML #HRMDS. BH-30236 is a novel, oral, macrocyclic, ATP-competitive, highly potent and selective CLK inhibitor designed to address dysregulated RNA splicing events that drive tumor growth and disease progression. Chief Medical Officer Geoff Oxnard, M.D., explains, "Targeting the spliceosome offers a new opportunity to expand the targetable proteome, potentially addressing treatment resistance in a new way." Learn more about the presentation, BH-30236, and the ongoing trial currently enrolling: https://lnkd.in/esAHiRNb

BlossomHill Therapeutics is hiring a Senior Director, Medical Writing!

Today, we are proud to share preliminary findings from the dose escalation portion of our ongoing, first-in-human Phase 1/2 #SOLARATrial of BH-30643 in patients with locally advanced or metastatic #EGFR-mutant #NSCLC at the #AACR-#NCI-#EORTC International Conference on Molecular Targets and Cancer Therapeutics. In these encouraging early results, our OMNI-EGFR™ inhibitor, BH-30643, shows promising potential to overcome limitations seen with the field’s predecessor EGFR inhibitors. The poster features several case examples demonstrating tumor reductions in heavily pretreated EGFR-mutant NSCLC patients, including those with various complex and difficult-to-treat mutations. BH-30643’s distinctiveness stems from its novel macrocyclic architecture, setting it apart from many current EGFR inhibitors that repurpose chemical scaffolds from earlier generations. Learn more about the presentation, BH-30643 and the Phase 1/2 SOLARA trial currently enrolling: https://lnkd.in/er2XMrt5

We are excited to share today that we will be at the #AACR-#NCI-#EORTC International Conference on Molecular Targets and Cancer Therapeutics with a poster presenting preliminary findings from the dose escalation portion of our ongoing, first-in-human Phase 1/2 #SOLARA trial of BH-30643 in #NSCLC. Designed for super-potency against a broad spectrum of mutations, including #resistance and #atypical mutations, in the #EGFR kinase domain, BH-30643 is a first-in-class, macrocyclic, non-covalent, OMNI-EGFR™ inhibitor. Learn more about the presentation, BH-30643 and the Phase 1/2 SOLARA trial current enrolling: https://lnkd.in/esbk6Gjs We are thrilled to share these preliminary findings and continue to build upon the enthusiasm behind the potential for our OMNI-EGFR™ inhibitor. We look forward to showing these findings and continuing our work to reach even more patients with this difficult disease.

BLOSSOMHILL THERAPEUTICS INC is hiring a Senior Director, Medical Writing!

BLOSSOMHILL THERAPEUTICS INC is hiring a Senior Director, Medical Writing!

Job Opening at BLOSSOMHILL THERAPEUTICS INC for Executive Director, Translational Medicine & Biomarker Science.